Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Int Rev Cell Mol Biol. 2019;343:219-297. doi: 10.1016/bs.ircmb.2018.06.001. Epub 2018 Aug 10.
Multiple myeloma (MM) is the second most common hematological malignancy and results from the clonal amplification of plasma cells. Despite recent advances in treatment, MM remains incurable with a median survival time of only 5-6years, thus necessitating further insights into MM biology and exploitation of novel therapeutic approaches. Both the ubiquitin proteasome system (UPS) and the PI3K/Akt/mTOR signaling pathways have been implicated in the pathogenesis, and treatment of MM and different lines of evidence suggest a close cross talk between these central cell-regulatory signaling networks. In this review, we outline the interplay between the UPS and mTOR pathways and discuss their implications for the pathophysiology and therapy of MM.
多发性骨髓瘤（MM）是第二常见的血液系统恶性肿瘤，源于浆细胞的克隆扩增。尽管最近在治疗方面取得了进展，但 MM 仍然无法治愈，中位生存时间仅为 5-6 年，因此需要进一步深入了解 MM 的生物学特性并开发新的治疗方法。泛素蛋白酶体系统（UPS）和 PI3K/Akt/mTOR 信号通路都与 MM 的发病机制和治疗有关，并且不同的证据表明这些核心细胞调控信号网络之间存在密切的相互作用。在这篇综述中，我们概述了 UPS 和 mTOR 通路之间的相互作用，并讨论了它们对 MM 的病理生理学和治疗的影响。
